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Abstract
Vitamin K2 binds to the intranuclear receptor SXR and results in the activation of a pleth-
ora of genes, both directly and indirectly. Among these genes are important biological 
markers of cellular characteristics or features (also known as cell phenotypes), as well as 
a set of molecules known to be involved in both hormone-induced, G-protein-mediated 
cell signalling, either directly or indirectly activating so-called sirtuins and/or histone 
deacetylaces (HDACs), known as determinants of cell types and their specific functions 
in a given tissue. Hence, vitamin K2 may be closely involved in or serving as a traditional 
molecular ‘link’ between hormonal receptors and intracellular signalling pathways. It 
has been stated that a true hormone is a product of living cells, which circulates in body 
fluids (such as blood) and elicits a specific and often stimulatory effect on the activity of 
cells situated remotely from its point of origin. A large bulk of evidence published over 
the past 10 years establishes vitamin K2 in this category of substances. Hence, vitamin K2 
should be considered and consequently classified as a hormone.
Keywords: vitamin K2, SXR, G-proteins, vitamin A-D-K2 cascade, bioinformatics,  
in vitro model systems
1. Introduction
Vitamin K has since more than 25 years been known to serve as a powerful nutrient factor 
in the preservation of homeostatic bone turnover, along with blood clotting biochemistry. In 
addition, vitamin K has been used as a therapeutic remedy in the clinic to treat and prevent 
bone brittleness (osteoporosis) in Japan and many other countries around the world. Moreover, 
beyond its enzymatic character as a cofactor for the vitamin K-dependent GGCX (gamma-
glutamyl carboxylase), Professor Inoue and his co-workers have shown that the K2 variant is, 
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in fact, a transcriptional modulator of osseous marker genes, also serving as an extracellular 
matrix-related molecule, via the stimulation of the ‘steroid and xenobiotic receptor’ SXR [1]. A 
microarray-based revelation of the present action of vitamin K2 in bone-derived osteoblastic cell 
genes corroborated the notion that the K2 variant menaquinone-4 (MK-4), in fact, is a hormone. 
Among the significantly upregulated genes, both growth differentiation factor 15 (GDF15) and 
stanniocalcin 2 (STC2) were concluded to serve as novel target genes, which both circumvented 
the traditional GGCX- and SXR-mediated pathways found in osteoblast-like cells.
2. Vitamin K2: vitamin and hormone
The induction of both GDF15 and STC2 genes is construed as specific to MK-4, since it was 
shown not to be brought about by another vitamin K(2) isoform MK-7, vitamin K(1) or the 
MK-4 side chain containing the geranylgeraniol group. A survey into the signalling pathways 
in question indicated that MK-4 sustained phosphorylation of protein kinase A (PKA) and 
that MK-4 mediated upregulation of genes, such as GDF15 and STC2, was diminished by the 
exposure to a PKA inhibitor or by siRNA constructs against PKA. These observations were 
in line with the concept that vitamin K(2) was capable of modulating its own target gene 
expression in bone-derived (osteoblastic) cell entities through a PKA-driven pathway, which 
in essence was different from the traditional vitamin K-dependent signalling pathways [2].
Vitamin K2 has been included as a member in a group of molecules, constituting the ‘require-
ment’ for blood to coagulate; however, it has been demonstrated to function or serve as a key in 
the homeostasis of osseous tissue, thus showing effectiveness as one therapeutic agent, among 
others, in the curative treatment portfolio of bone ailments and diseases, i.e. like bone loss or 
brittleness (osteomalacia and osteoporosis). Furthermore, it has, since several decades, been 
acknowledged that vitamin K2 mediates transcriptional modulation of marker genes in osteo-
blastic cells, as well as reinforcing bone formation via the nuclear steroid and xenobiotic recep-
tor, SXR. In this context, Dr. Satoshi Inoue and his research team identified several genes, which 
were upregulated by vitamin K2 (and a prototypical SXR like ligand, rifampicin) in osteoblastic 
cells, through microarray analysis and PCR. A plethora of genes was upregulated, among which 
collagen synthesis and accumulation in osteoblast-like MG63 cells were enhanced several times 
over by vitamin K2 treatment. Therefore, the results of Dr. Inoue and his research group more 
than suggested a novel function for vitamin K2 in the formation of osseous tissues, i.e. that K2 
was a true transcriptional regulator of extracellular matrix-related genes, being involved in the 
assembly of collagen. At present, we know that vitamin K2 (or menaquinone-7 = MK-7, among 
other vitamin K2 metabolites) works through this nuclear receptor and consequently should be 
classified as a hormone and not solely be construed as ‘a vitamin’.
Arterial stiffness is always associated with an enhanced cardiovascular risk, morbidity and 
mortality [3]. The present article reviews the main vitamins being involved in arterial stiff-
ness and enabling destiffening; their mechanism of action, providing a brief description of 
the latest studies in the area; and their implications for primary cardiovascular prevention, 
clinical practice and therapy. Despite inconsistent proof for ‘softening’ brought about by 
vitamin supplementation in a plethora of clinical trials, promising results were observed in 
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selected populations. The chief mechanisms pertain to anti-atherogenic potential, substantial 
augmentation of endothelial functionality (pertaining to vitamins A, C, D and E, respectively) 
and general metabolic profiling (pertaining to vitamins A, B12, C, D and K, respectively), sup-
pression of the renin-angiotensin-aldosterone (R-R-A) system (vitamin D), anti-inflammatory 
(vitamins A-D-E-K) and antioxidant effects (vitamins A-C-E), diminished homocysteine lev-
els (vitamin B12) and a reversal of the calcification of arteries (vitamin K). Vitamins A, B12, 
C, D and E, as well as vitamin K status, are important in evaluating the risk of cardiovascular 
events, and, finally, supplementation with vitamins may serve as an efficient, individually 
based and less costly ‘destiffening’ therapeutic mode.
Vitamin K is renowned for being an important (vital) nutrient, sustaining both bone homeo-
stasis and blood coagulation. Therefore, it is both clinically and ubiquitously used as a thera-
peutic agent or treatment for osteoporosis in Japan and western countries. Besides its powerful 
enzymatic, cofactor role of the vitamin K-dependent g-glutamyl carboxylase (GGCX), it has 
since long been known that vitamin K2 may serve as a transcriptional regulator of marker 
osteoblastic genes, as well as in matrix-related, extracellular genes. In this context the activa-
tion of the so-called steroid and xenobiotic receptor (known as SXR) is mandatory.
Hence, genes known to be upregulated by vitamin K2 isoforms like menaquinone-4 (MK-4) 
were applied using oligonucleotide-based microarray analyses. Among the MK-4 upregu-
lated gene species, the growth differentiation factor 15 (GDF15) and stanniocalcin 2 (STC2) 
were discovered as new MK-4 target genes, being independent of the GGCX and SXR path-
ways in osteoblastic cells. The observed induction of GDF15 and STC2 was construed as 
specific to MK-4, since it was not seen with exposure to MK-7 or vitamin K1. Surprisingly, a 
scrutiny of the main signalling pathways showed that MK-4 stimulated PKA (protein kinase 
A) phosphorylation. Furthermore, the MK-4-dependent induction of both GDF15 and STC2 
genes was obliterated subsequent to the treatment with PKA inhibitors or siRNAs against 
PKA. Therefore, it was postulated that vitamin K2 (MK-7) could modulate target gene expres-
sion in osteoblastic cells via PKA-dependent mechanisms, which were distinct from any pre-
viously known vitamin K-mediated signalling pathway.
The paper found that vitamin K2 is recognised, along with calcium, vitamin D and magne-
sium, as essential in supporting strong bones and healthy arteries. In the paper, Nutritional 
strategies for skeletal and cardiovascular health: hard bones, soft arteries, rather than vice versa, the 
authors cite a US Surgeon General’s Report that states that one in two Americans over 50 is 
expected to have or to be at risk of developing osteoporosis, which causes 8.9 million fractures 
annually, with an estimated cumulative cost of incident fractures predicted at $474 billion 
during the next 20 years in the USA.
Furthermore, a study conducted by the Mayo Clinic [4, 5] reported that ‘compared with 30 
years ago, forearm fractures have risen more than 32% in boys and 56% in girls’. Meanwhile, 
strong epidemiological associations exist between decreased bone mineral density (BMD) 
and increased risk of cardiovascular (CV) disease. For example, individuals with osteoporosis 
have a higher risk of coronary artery disease and vice versa. This problem will be magnified, 
according to the paper, if the therapies for osteoporosis (calcium supplements) independently 
increase risk of myocardial infarction. To that end, the authors conducted a comprehensive and 
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systematic review of the scientific literature to determine the optimal dietary strategies and 
nutritional supplements for long-term skeletal health and cardiovascular health. They sum-
marised what is helpful for building strong bones while maintaining soft and supple arteries:
• Obtain calcium from dietary sources (the best choice is a calcium hydroxyapatite) with the 
adequate animal protein, fruit and vegetable intake.
• Concomitantly increase potassium consumption, while reducing sodium intake should be 
taken into account.
• Maintain vitamin D levels in the normal range.
• Increase the intake of foods rich in vitamins K1 and K2.
The study notes: ‘A meta-analysis concluded that while supplementation with phytonadione 
(vitamin K1) improved bone health, vitamin K2 was even more effective in this regard. This 
large and statistically rigorous meta-analysis concluded that high vitamin K2 levels were 
associated with reduced vertebral fractures by approximately 60%, hip fractures by 77% and 
all non-vertebral fractures by approximately 81%. Supplementation with vitamin K2 as MK-7 
increased bone strength in postmenopausal women in 3-year clinical study’.
‘Additionally, increased vitamin K2 intake has been associated with decreased arterial cal-
cium deposition and the ability to reverse vascular calcification in animal models. Moreover 
clinical trial proved that vitamin K2 supplementation increases elasticity of the arteries (in 
3 years)’, the paper stated. The authors recommend increasing the intake of foods rich in 
vitamins K1 and K2 to secure skeletal and cardiovascular health. ‘The positive health poten-
tial of vitamin K2 is more effective than for vitamin K1, the paper reads. Yet, Dr. Hogne 
Vik, Chief Medical Officer with NattoPharma, world leader in vitamin K2 R&D, exclusive 
global supplier of MenaQ7 vitamin K2 as MK-7, and sponsor of the 3-year studies cited in 
the paper, explains that it is not possible to get sufficient amounts of vitamin K2 through a 
European or US diet’.
The only food that contains enough vitamin K2 is the Japanese dish Natto. ‘This means that 
if you want to get enough vitamin K2 into your body, then you have to take dietary supple-
ments or functional foods containing vitamin K2’, he said. ‘We are gratified, but not surprised, 
that our 3-year clinical studies were cited in this paper’, Dr. Vik continues. ‘NattoPharma has 
driven the clinical research that has demonstrated vitamin K2’s benefits for human health, 
and our breakthrough studies provided the first intervention data confirming the associations 
that observational studies made previously: that vitamin K2 as MK-7 is available beyond the 
liver to support bone and cardiovascular health. And it does this by activating proteins that 
help the body to properly utilise calcium – there by simultaneously supporting both skeletal 
and cardiovascular health’.
How are we going to interpret the above-described information about the mechanism of 
action of vitamin K2? Well, according to the definition given in dictionaries and scientific 
papers, vitamin K2 (as in the form or MK-4 or MK-7) fits this definition and should be classi-
fied as one.
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3. What features characterise a true hormone?
To make the picture clearer, let us start all over again. According to Figure 1, the impact of 
a hormone is one signal among differentiation signals (also called epigenator factors), which 
may be temperature variations, oxygen tension, mechano-stimulation or humoral factor/
hormones. The ‘hormone’ eventually activates a transcription factor or microRNA synthesis, 
which may impinge upon DNA in terms of a certain or given spectrum of mRNAs appearing 
in the cytosol of the cell. Of major interest here are eventually two classes of molecules utmost 
important for the acquisition of the final cell phenotype—the histones and the sirtuins (see 
Figure 5).
The response elicited by a single hormone (epigenator) may look like the network of interact-
ing factors (mostly transcription factors), such as the network representing the closely cooper-
ating network (mostly represented by transcription factor), as seen in Figure 2a and b.
The reader is recommended to look up the remainder of the genes shown above and will be 
amazed as to the plethora of biological effects being modulated (directly and/or indirectly) 
by the nuclear receptor NR1/NR2 = SXR, to which vitamin K2 binds, exerting its multitude of 
biological effects. The crucial question is then: what may be the immediate effect of vitamin 
K2 (e.g. MK-7) on cell phenotype, for example, on bone chips harbouring live osteoblastic 
cells? In Figure 3, bovine chips from young calves were incubated for 14 days in growth 
medium, which were analysed for osteocalcin, IL-10, TGFβ, OPG and RANKL (osteoblast and 
osteoclast markers), respectively. For detailed summary of results, see Figure 3.
Figure 1. The epigenator-initiator-maintainer model of hormonal impact on the phenotype of a given cell. The hormone 
(binding to a given receptor—here represented by two different transmembrane proteins) will eventually elicit a 
response determined by the joint effect of transcription factors and microRNAs determining the end-point effect of the 
epigenator, such as cell differentiation and/or efflux of secretory products.
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Figure 3. Bovine chips from young calves incubated as stated above. The chips were (a) incubated for 7 or 21 days and 
analysed for osteocalcin, IL-10, TGFβ, OPG and RANKL (all parameters’ characteristics for the osteoblast phenotype); 
(b) incubated for 7 days and thereafter for 14 days in the presence of either vitamin K2 = MK-7; siRNA against the 
vitamin K2 receptor SXR or with pre-mir-760. The final measurements of secretory products were as indicated above 
(osteocalcin, IL-10, TGFβ, OPG and RANKL).
Figure 2. (a) and (b) GeneCards-based emulation of molecules interacting with NR1/NR2 (which is identical to SXR, 
identified/described by the Japanese researcher, Professor Satoshi Inoue). Interestingly, NR1/NR2 is integrated in a 
large network of interacting molecules (genes), representing various classes of transcription factors (e.g. PPARG, RORC, 
RARA, RXR) and not to forget the thyroid receptors A and B!
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The interpretation of the experiment with ‘live’ bovine bone chips is the following: since MK-7 
(a vitamin K2 analogue) is stimulated, while SXR siRNA and pre-mir-760 markedly reduced 
the secretory profile of the bovine osteoblast, it was concluded that the effect of vitamin K2 
(MK-7) on the osteoblast profile of secretory molecules was stimulatory and that the effect of 
vitamin K2 was mediated solely through the action of the nuclear receptor SXR.
Furthermore, it was shown that one well-known and well-represented vitamin K2 ‘analogue’ 
(MK-7) was able to activate (upregulate) some of the members of the FoxA and FoxO family 
of transcription factors. In our hands, vitamin K2 analogue MK-7 (and to a lesser extent MK-4) 
was able to substitute for insulin, as well as some growth factors (like growth hormone and a 
few interleukins (not shown)) (Figure 4).
Figure 5 shows a strong relationship (network between a human osteoblast microRNA pro-
file, respectively, and a well-known plethora of marker genes) which has previously been 
listed according to their sequential appearance as the osteoblast develops from a stem cell into 
a ‘full-blown’, mature mineralizing osteoblast. By adding a plethora of transcription factors, 
sirtuins (SIRTs), histone deacetylases (HDACs) and transcription factors (with special refer-
ences to the osteoblastic phenotype), a distinct pattern of interaction appeared. By adding 
vitamin K2, i.e. MK-7 and/or SXR, to the system, a similar pattern appeared (not shown1). 
This was also the case for other tissues as well, e.g. lung, heart, brain, muscle, white/beige fat 
tissues and many others (not mentioned here2).
1Details not included—patents pending.
2Details not included—patents pending.
Figure 4. The impact of insulin and growth factors (GFs) on members of the FoxA and FoxO families of insulin and 
growth factors.
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